BRIEF-Gilead Sciences submits new drug application to U.S. FDA for Hepatitis C By: Reuters: Company News December 08, 2016 at 08:58 AM EST * Gilead Sciences Inc - nda for sof/vel/vox is based on data from two phase 3 studies (polaris-1 and polaris-4) Read More >> Related Stocks: Gilead Sciences